<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640844</url>
  </required_header>
  <id_info>
    <org_study_id>2020-13</org_study_id>
    <secondary_id>2020-A00686-33</secondary_id>
    <nct_id>NCT04640844</nct_id>
  </id_info>
  <brief_title>Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia</brief_title>
  <acronym>RIMACI</acronym>
  <official_title>Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chronic coronary artery disease could be detected by a drop in the expression of A2A&#xD;
      receptors to adenosine, while high values of the KD / EC50 ratio are a sign of coronary&#xD;
      ischemia. Knowing the number of A2A receptors in circulating lymphocytes could allow&#xD;
      detection of coronary artery disease and evaluating the functionality of A2A receptors in&#xD;
      circulating lymphocytes could allow quantification of myocardial ischemia.&#xD;
&#xD;
      Thus, a simple and unique blood sample would quickly detect patients with life-threatening&#xD;
      coronary ischemia. This would avoid prolonged hospitalizations and costly non-invasive tests&#xD;
      (stress echocardiography, myocardial scintigraphy) in patients without coronary artery&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the discriminating capacities of A2A&#xD;
      adenosine receptors expression on the surface of circulating lymphocytes for the detection of&#xD;
      coronary artery disease in patients hospitalized for surgery of the aorta and / or arteries&#xD;
      of the lower limbs.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
      Assessment of the discriminating capacities of the functionality (KD / EC50) of A2A adenosine&#xD;
      receptors on the surface of circulating lymphocytes, for the diagnosis of myocardial ischemia&#xD;
      in patients hospitalized for surgery of the aorta and / or arteries of legs.&#xD;
&#xD;
      Determinate the best threshold for discriminating patients with coronary artery disease and&#xD;
      estimate the discriminating performance associated with this threshold.&#xD;
&#xD;
      Determinate the best threshold for discriminating patients with myocardial ischemia and&#xD;
      estimate the discriminating performance associated with this threshold.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of adenosine</measure>
    <time_frame>24 MONTHS</time_frame>
    <description>measuring the expression and function of lymphocyte A2A receptors.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Chronic Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>patients hospitalized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for surgery of the aorta and / or arteries of the lower limbs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>measuring the expression and function of lymphocyte A2A receptors.</description>
    <arm_group_label>patients hospitalized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted for preoperative assessment of vascular surgery of the aorta and /&#xD;
             or arteries of the lower limbs.&#xD;
&#xD;
          -  Adult person (age&gt; 18).&#xD;
&#xD;
          -  Affiliated with a social security scheme.&#xD;
&#xD;
          -  Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of coronary artery disease awaiting revascularization.&#xD;
&#xD;
          -  Hyperthyroidism, anemia (Hb &lt;13 g / dL).&#xD;
&#xD;
          -  Contraindication to the practice of coronary angiography, stress echocardiography or&#xD;
             myocardial scintigraphy.&#xD;
&#xD;
          -  Unstable hemodynamic state or cardiogenic shock.&#xD;
&#xD;
          -  Adults protected under guardianship, curatorship or legal protection.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie GARRIDO PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ALAEXANDRA GIULIANI</last_name>
    <phone>0491382747</phone>
    <email>alexandra.giuliani@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PIERRE DEHARO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

